TG Therapeutics (NASDAQ:TGTX) Raised to Hold at StockNews.com

TG Therapeutics (NASDAQ:TGTX) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

A number of other analysts have also issued reports on the company. The Goldman Sachs Group boosted their price target on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. HC Wainwright boosted their target price on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. TD Cowen began coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $50.00 price objective for the company. Finally, JPMorgan Chase & Co. raised their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, November 25th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.67.

TG Therapeutics Stock Performance

NASDAQ:TGTX opened at $28.77 on Tuesday. The company has a market cap of $4.48 billion, a price-to-earnings ratio of -287.67 and a beta of 2.24. TG Therapeutics has a 1 year low of $12.84 and a 1 year high of $36.84. The stock’s 50 day simple moving average is $31.37 and its two-hundred day simple moving average is $25.25. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). The company had revenue of $83.90 million during the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. TG Therapeutics’s revenue for the quarter was down 49.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.73 earnings per share. As a group, equities analysts anticipate that TG Therapeutics will post 0.17 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction on Monday, November 11th. The stock was sold at an average price of $30.44, for a total transaction of $152,200.00. Following the transaction, the director now owns 100,195 shares in the company, valued at $3,049,935.80. The trade was a 4.75 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Sean A. Power sold 11,337 shares of TG Therapeutics stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $30.29, for a total transaction of $343,397.73. Following the sale, the chief financial officer now directly owns 670,632 shares in the company, valued at approximately $20,313,443.28. The trade was a 1.66 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 26,358 shares of company stock worth $781,497. 10.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On TG Therapeutics

Large investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC grew its position in shares of TG Therapeutics by 562.4% in the 4th quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock valued at $77,000 after buying an additional 2,171 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of TG Therapeutics by 60.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company’s stock worth $16,859,000 after purchasing an additional 270,286 shares during the last quarter. Principal Financial Group Inc. increased its position in TG Therapeutics by 1,549.4% during the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock worth $18,061,000 after purchasing an additional 725,371 shares in the last quarter. Franklin Resources Inc. boosted its position in TG Therapeutics by 3.8% during the third quarter. Franklin Resources Inc. now owns 128,985 shares of the biopharmaceutical company’s stock worth $2,945,000 after acquiring an additional 4,756 shares during the last quarter. Finally, Synovus Financial Corp acquired a new position in TG Therapeutics in the third quarter valued at $465,000. 58.58% of the stock is owned by hedge funds and other institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.